A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
A Phase 1/2, Open Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination With Other Antileukemic Agents in Participants With Selected Myeloid Malignancies
The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), or chronic myelomonocytic leukemia (CMML). Part 1A dose escalation will determine the RDE to be used in a future expansion stage of the trial. An optional Part 1B drug-drug interaction (DDI) substudy will evaluate the effect of posaconazole on the PK of S241656.
The study consists of a screening period of up to 21 days, a treatment period consisting of continuous 28-day cycles of treatment, an end-of-treatment visit, a safety follow-up period, and long-term disease and survival follow-up every 3 months. Participants in the optional DDI substudy may continue treatment in the main study following completion of the DDI assessment period. Participants may undergo bone marrow aspirates and/or biopsies, blood tests, electrocardiograms (ECGs), echocardiograms or multigated acquisition (MUGA) scans, physical examinations, ophthalmologic assessments, and disease response questionnaires.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Institut de Recherches Internationales Servier (I.R.I.S.)
- Número de telefone: +33 1 55 72 60 00
- E-mail: scientificinformation@servier.com
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
- Investigator-assessed life expectancy of ≥ 3 months.
- Able and willing to comply with requirements of the study protocol.
- Documented genetic characterization of the disease as per local practice.
- Clinical and laboratory thresholds:
- Cytoreduction: white blood cell (WBC) < 25 × 10⁹/L (hydroxyurea/cytarabine/leukapheresis allowed).
- Renal: creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault).
- Hepatic: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN) (5 × if leukemic); Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome).
- Part 1 Only: Relapsed/Refractory (R/R), pathologically confirmed AML, MDS/AML, or CMML.
- Part 1 Only: Must have failed ≥ 1 approved standard therapy and have no other approved standard options.
Exclusion Criteria:
- Known hypersensitivity to S241656, or Posaconazole (Part 1B).
- Pregnant or breastfeeding; positive serum pregnancy test for WOCBP.
- Diagnosis of acute promyelocytic leukemia (French-American-British [FAB] M3 classification), MPN, mixed/ambiguous lineage, histiocytic/dendritic cell neoplasms, or AML with isolated extramedullary disease (no marrow/blood involvement).
- Active Central Nervous System (CNS) disease (by cytologic or radiographic evidence).
- Failure to recover to ≤ Grade 1 from previous toxicities (except Grade 2 neuropathy/alopecia).
- Major surgery within 4 weeks.
- Any anticancer therapy within 2 weeks or 5 half-lives (28 days for biologics). Cytoreduction with hydroxyurea or cytarabine is permitted.
- Prior use of experimental KRAS/BRAF/MEK/ERK inhibitors (prior FLT3 inhibitors are permitted).
- Uncontrolled infections (human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) permitted only if viral load is undetectable/controlled and specific cluster of differentiation 4 (CD4)+ criteria are met).
- Malabsorption, Crohn's, or chronic vomiting that impacts oral drug absorption.
- History/risk of retinal vein occlusion (RVO), glaucoma, or hyper-viscosity syndromes.
- Other active malignancy requiring systemic therapy within 2 years (except non-melanoma skin cancer or localized/cured tumors).
- Stroke, myocardial infarction (MI), unstable angina, or acute coronary syndrome within 6 months.
- Congestive heart failure (CHF), clinically significant cardiac arrhythmias according to the investigator's judgement (e.g., ventricular tachycardia), complete left bundle branch block and high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II- and third degree AV block).
- Fridericia-corrected QT interval (QTcF) > 470 msec or history of Torsades de pointes.
- Disseminated intravascular coagulation (DIC), significant coagulopathy according to the investigator's judgement, or uncontrolled bleeding.
- Proton Pump Inhibitors (PPIs) and potassium-competitive acid blockers ≥ 7 days prior to Cycle 1 Day 1.
- Breast cancer resistance protein (BCRP) sensitive substrate or with a narrow therapeutic index (NTI)
- All herbal preparations/supplements are prohibited.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Part 1A: Dose Escalation
|
Tablets taken by mouth.
|
|
Experimental: Part 1B: Optional Drug-Drug Interaction [DDI] Substudy
|
Tablets taken by mouth.
Tablets taken by mouth
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
(Part 1A and 1B) Dose limiting toxicity (DLTs) associated with S241656 during the first cycle of treatment
Prazo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1A and 1B) Number of Adverse Events (AEs)
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of Serious Adverse Events (SAEs)
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Severity of AEs
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Severity of SAEs
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of AEs
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of SAEs
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of changes in safety laboratory results
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of changes in physical examination
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose reductions due to AEs
Prazo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose interruptions due to AEs
Prazo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose delays due to AEs
Prazo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of study withdrawals due to AEs
Prazo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1B only) Maximum concentration (Cmax) of S241656
Prazo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Cmax of metabolite S243796
Prazo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Time corresponding to Cmax (Tmax) of S241656
Prazo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Tmax of metabolite S243796
Prazo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Terminal half-life (t1/2) of S241656
Prazo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) t1/2 of metabolite S243796
Prazo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Area under the curve (AUC) of S241656
Prazo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) AUC of metabolite S243796
Prazo: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
(Part 1A only) Cmax of S241656
Prazo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Cmax of metabolite S243796
Prazo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Tmax of S241656
Prazo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Tmax of metabolite S243796
Prazo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) AUC of S241656
Prazo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) AUC of metabolite S243796
Prazo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) t1/2 of S241656
Prazo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) t1/2 of metabolite S243796
Prazo: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A and 1B) Complete remission (CR)
Prazo: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Complete remission with incomplete hematologic recovery (CRi)
Prazo: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Morphologic leukemia free state (MLFS)
Prazo: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Complete remission with partial hematologic recovery (CRh)
Prazo: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Partial response (PR)
Prazo: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Objective response (OR)
Prazo: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Composite complete remission (CRc)
Prazo: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Red blood cell (RBC) and platelet transfusion independence for at least 8 weeks
Prazo: Through end of treatment, up to approximately 4 years
|
In participants with AML or MDS/AML only
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of response (DOR)
Prazo: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Time to response (TTR)
Prazo: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Event free survival (EFS)
Prazo: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Overall survival (OS)
Prazo: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Marrow response
Prazo: Through end of treatment, up to approximately 4 years
|
In participants with CMML only
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of participants with erythroid-, neutrophil-, platelet or spleen-response
Prazo: Through end of treatment, up to approximately 4 years
|
In participants with CMML only
|
Through end of treatment, up to approximately 4 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Neoplasias
- Doença crônica
- Atributos da doença
- Doenças Genéticas, Congênitas
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Leucemia Mieloide
- Doenças mielodisplásicas-mieloproliferativas
- Doenças da Medula Óssea
- Leucemia
- Síndromes Mielodisplásicas
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Condições Patológicas, Sinais e Sintomas
- Doenças hemic e linfáticas
- Deficiência de GATA2
- Leucemia Mieloide Aguda
- Leucemia Mielomonocítica Crônica
- posaconazol
Outros números de identificação do estudo
Outros números de identificação do estudo
- S241656-292
- 2025-525128-88-00 (Ctis)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
Access can be requested for all interventional clinical studies:
- used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
- where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.
In addition, access can be requested for all interventional clinical studies in patients:
- sponsored by Servier
- with a first patient enrolled as of 1 January 2004 onwards
- for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .